Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Injectable cabotegravir and rilpivirine are approved for people with viral suppression who would prefer monthly injections to daily pills.
Whether for treatment or prevention, women’s interest in injectable antiretrovirals varied based on their relationship with injection.
A clinical trial found that switching HIV meds to long-acting Cabenuva may not require oral lead-in.
COVID-19, HIV vaccines, cure news and long-acting injectables stood out among the top HIV treatment stories of the year.
The European Medicines Agency gave the green light to injectable cabotegravir and rilpivirine for HIV treatment.
A study analyzed how well people with HIV and their health care providers can navigate the experimental long-acting injectable Cabenuva.
After years of taking daily oral cabotegravir and Edurant, people with suppressed HIV switched to long-acting injectable Cabenuva.
A study found no difference in outcomes based on whether participants took oral meds for a month before switching to injectables.
The placebo-controlled trial compared injections of cabotegravir given every eight weeks versus daily Truvada as PrEP.
Whether given every four or eight weeks, long-acting injections of cabotegravir and rilpivirine suppressed HIV equally well.
A majority of women interviewed in a small study expressed a preference for monthly injectable treatment over daily pills.
A rundown of POZ’s reporting on the 2020 Conference on Retroviruses and Opportunistic Infections
The Food and Drug Administration declined approval of ViiV Healthcare’s injectable HIV regimen Cabenuva.
The FDA recently held up the U.S. approval based on concerns over the monthly injectable regimen’s manufacturing.
Attendees will hear news about the second probable HIV cure, long-acting injectable meds and COVID-19.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.